Corticotroph Adenoma, Cushing's Disease
Conditions
Keywords
Cabergoline
Brief summary
This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.
Interventions
DRUGCabergoline
Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
Sponsors
Seth Gordhandas Sunderdas Medical College
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology
Exclusion criteria
* Patient's intolerance to drug or known sensitivity to ergot derivatives * Pregnancy, lactation or female wishing to be pregnant * Any serious medical illness * Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl | — |
Countries
India
Outcome results
None listed